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Awareness.Abstract Rational: To date in Egypt there is no available national registry for PH cases therefore
this study had two objectives, first to record the clinical characteristics and demographics of PH
cases in a single center study that hopefully could be a stepping stone in the development of a
national registry. The second objective was to assess the awareness of the physicians of the disease.
Methods: It included two parts, the first a retrospective descriptive study of 52 patients diag-
nosed as PH who were admitted to Abassia Chest Hospital in the period between January 2011
and December 2012. The second part comprised a prospective assessment of the awareness of 40
specialized chest physicians who worked in Abassia Chest Hospital using a questionnaire.
Results: Among the 52 patients the mean age was 55.8 ± 13.25 years, 28 females (53.8%) and 24
males (46.2%) and a mean cigarette smoking index of 78.5 (±33.3). The patients suffered from
slight respiratory acidosis with a mean pH of 7.3 (±0.03) explained by the elevated mean PaCO2
of 49.9 (±8.6) mmHg and hypoxemia explained by a mean PaO2 of 73.6 (±12.7) mmHg, and a
mean SO2 of 83.9 (±5)%. According to NYHA, 40 (76.9%) presented in FC III and 12 (23.1%)
FC IV. ECHO assessment records revealed an elevated right ventricular systolic pressure (RVSP)
with an estimated mean of 61.4 (±12.4) mmHg, tricuspid regurge was the most common valve
affection in 38 (73%) of the cases while 18 (34.6%) had left ventricular diastolic dysfunction and
left ventricular hypertrophy. Almost all of the diagnosed patients with PH 43/52 (82.6%) were clas-
sified as group 3 that is PH due to lung diseases and/or hypoxemia. COPD contributed to slightlyal blood
chronic
ic heart
tandard
rculosis.
296 M. Farrag et al.more than half of the 29 (55.7%) cases meanwhile the other half was shared between variable lung
diseases. PH due to left sided heart failure (group 2) was the second common cause 5/52 (9.6%) fol-
lowed equally by patients with chronic thromboembolism (CTEPH) (group 4) 2/52 (3.8%) and
patients with idiopathic pulmonary hypertension (group 1) 2/52 (3.8%). Among the 40 physicians
enrolled in the survey only 15 (37.5%) acknowledged that they found PH a commonly diagnosed
disease in their practice. As regards the method of investigation; 34 (85%) decided on ECHO only
but 5 (12.5%) recommended both ECG and ECHO. To reach a confirmed diagnosis of PH only 2
(5%) selected right heart catheterization while 35 (87.5%) chose elevated RVSP > 25 mmHg and 3
(7.5%) didn’t know. None of the physicians conducted clinical trials on PH medications also none
of them have previously referred any of the PH cases for heart and lung transplant and only 1 physi-
cian referred 1 case for thrombo-endarterectomy. Lastly 34 (85%) of the physicians didn’t attend
any educational meeting concerning PH, the remaining 4 (10%) attended one meeting and 2
(5%) attended two meetings.
Conclusion: In conclusion the study provides information on the clinical and epidemiological
features of PH in Egypt as a primary pilot study. It highlights the fact that awareness about the
disease is still lacking among physicians and/or health care providers and late detection continues
to be a threat for optimum management of PH.
Clinical impact: It unveiled the urgent need for a large scale registry not only national but also
regional using uniform diagnostic criteria based on the latest published guidelines.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pulmonary hypertension (PH) is a devastating disorder of the
cardiovascular system leading to right heart failure and death.
Although it was known for the last 100 years, only in the last
25–15 years a better understanding of pathogenesis and risk fac-
tors has led to new diagnostic and therapeutic approaches and
hence to an increased interest in the detection of this incurable
disease associated with poor survival and prognosis [1–3]. The
profile of PH varies throughout the world therefore obtaining
data about epidemiology, follow-up and prognosis is invaluable
to improve therapy and assess outcome parameters [4].
Major advances in the diagnosis and management of PH
have been in constant evolution and these achievements were
marked by the different World Symposia on Pulmonary
Hypertension (WSPH). The complexity of the recent interna-
tional guidelines for the diagnosis and assessment of patients
with PH during the 5th WSPH in 2013 as well as the published
data that the majority of PH cases are still diagnosed in a late
stage manifesting the urgent need to increase the awareness of
the doctors to achieve a better understanding of this multi-
system disorder [5].
To date in Egypt there is no available national registry for
PH cases therefore this study had two objectives, first to record
the clinical characteristics and demographics of PH cases in a
single center study that hopefully could be a stepping stone in
the development of a national registry. The second objective
was to assess the awareness of the physicians of the disease.Subjects and methods
This study was conducted in Abassia Chest Hospital in the
period between January 2011 and December 2012
It included two parts, the first a retrospective descriptive study
of 52 patients diagnosed as PH who were admitted to theAbassia Chest Hospital in the period between January 2011
and December 2012. It is important to note that although
current guidelines recommend right heart catheterization
(RHC) for the diagnostic evaluation of patients with PH, the
diagnostic approach in this study was established mainly in
the presence of clinical suspicion based on the accepted
definitions and trans-thoracic echocardiography recording
high pulmonary artery systolic pressure (PASP > 50 mmHg)
as the RHC wasn’t available [6].
The second part comprised a prospective assessment of the
awareness of 40 specialized chest physicians who worked in the
Abassia Chest Hospital using a questionnaire [7].
The questionnaire included 18 questions as follows:
(1) Is PH a common finding you met with?
(2) What are the common diseases that are complicated by
PH that you usually examine?
(3) How do you suspect that your patient developed PH?
(4) Do you care for chest X-ray findings in PH?
(5) Do you investigate for pulmonary hypertension if you
suspect it?
(6) How do you investigate?
(7) Do you usually ask for echocardiography as a routine in
cases suspected to develop pulmonary hypertension?
(8) When do you suspect idiopathic pulmonary
hypertension?
(9) When do you diagnose pulmonary hypertension as a
final diagnosis?
(10) Do you refer your patient to a specialized center or are
you the one who cares?
(11) What year did you begin caring for patients with PH?
(12) How many PH patients do you currently treat?
(13) Do you require all patients to undergo right heart
catheterization with vasodilator testing prior to prescrib-
ing a therapy for PH?
(14) What therapies do you prescribe for pulmonary
hypertension?
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(16) Have you referred patients for lung or heart/lung
transplant?
(17) Have you referred patients for pulmonary
thromboendarterectomy?
(18) Which educational meetings regarding PH have you
attended in the last two years?
Statistical analysis
Parametric data were expressed as mean ± standard deviation
(SD), minimum, maximum, and range, while non-parametric
data were expressed as number, and percentage. Chi-square
was used to study the relation between non parametric vari-
ables. Two tailed p value of <0.001 was considered highly sig-
nificant, and p< 0.05 was considered significant. Statistical
analyses were performed utilizing Statistical Package for Social
Sciences software (SPSS for Windows, version 15.0; SPSS Inc.,
Chicago, IL).
Results
Results of the studied population
The total number of the studied patients were 52 with a mean
age of 55.8 ± 13.25 years, among them 28 females (53.8%)
and 24 males (46.2%), most of the females 26 (92.8%) didn’t
work whereas 19 (79.1%) of the males worked in differentTable 1 The clinical characteristics of the recorded patients.
Number Percentage %
Pulmonary symptoms
Dyspnea 52 100
Wheeze 21 40.4
Orthopnea 12 23.1
Cough 15 28.8
Expectoration 11 21.2
Chest pain 2 3.8
Haemoptysis 2 3.8
Clinical examination
Hypertension 12 23
Tachypnea 10 19.2
Irregular pulse 4 7.7
Central cyanosis 22 42.3
Elevated jugular venous pulse 40 77
Lower limb edema 47 90.4
Wheezes 40 76.9
Crackles 25 48.1
S2* loud and splitting 11 21.2
S3^ 12 23.1
TR# murmur 24 46.2
WHO/NYHA functional class
I 0 0
II 0 0
III 40 76.9
IV 12 23.1
S2*: second heart sound; S3^: third heart sound; TR#: tricuspid
regurge; WHO/NYHA: World Health Organization modification
of New York Heart Association functional classification.occupations. As regards the residency the majority lived in
Cairo governorate 32 (61.5%) followed by Qalyubia gover-
norate 7 (13.5%) then Giza governorate 6 (11.5%) and 7
(13.5%) in others. 23 (44.2%) of the cases were cigarette smok-
ers with the mean 3.9 (±1.6) pack/day and mean cigarette
smoking index of 78.5 (±33.3). The clinical characteristics of
the recorded patients are illustrated in Table 1 from which it
is evident that based on the World Health Organization
(WHO) modification of the New York Heart Association
(NYHA) classification of PH [7] all the patients presented late
in FC III 40 (76.9%) and FC IV 12 (23.1%). Among the stud-
ied group co-morbid conditions were present as highlighted in
Fig. 1.
ABG findings for the patients revealed that all patients suf-
fered from slight respiratory acidosis with a mean pH of 7.3
(±0.03) explained by the elevated mean PaCO2 of 49.9
(±8.6) mmHg and hypoxemia explained by a mean PaO2 of
73.6 (±12.7) mmHg, and a mean SO2 of 83.9 (±5)%. The
mean HCO3 was 28.5 (±6.9) mmol/L and the mean ABE
was 5.19 (± 6.6) mEq/L.
Among the 52 ECG reports collected two predominant
findings were noticed equally in the form of right axis devia-
tion and P pulmonale in 33 (63%).
Retrospective ECHO assessment records revealed an ele-
vated right ventricular systolic pressure (RVSP) with an esti-
mated mean of 61.4 (±12.4) mmHg, tricuspid regurge was
the most common valve affection in 38 (73%) of the cases
while 18 (34.6%) had left ventricular diastolic dysfunction
and left ventricular hypertrophy. It is important to note that
some of the patients had more than one abnormality detected.
The clinical classification of PH among the cases is summed in
Table 2.
Referring to Table 2 it can be established that almost all the
diagnosed patients with PH 43/52 (82.6%) were classified asHypertension
26%
IHD
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Arrhythmias
6%
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Figure 1 Co-morbidity prevalence.
Table 2 The clinical classification of PH among the studied
cases.
Type Number Percentage
PH due to lung diseases and or hypoxemia
[G3]
43 82.6
PH due to left heart disease [G2] 5 9.7
Chronic thromboembolic PH (CTEPH)
[G4]
2 3.8
Idiopathic PH [G1] 2 3.8
G: group; PH: pulmonary hypertension.
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Figure 2 The prevalence of the different lung diseases among the
PH cases in group 3.
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Figure 3 The different types of medications prescribed by
physicians.
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COPD contributed to slightly more than half of the cases 29
(55.7%) meanwhile the other half was shared between variable
lung diseases as represented in Fig. 2.
Analysis of the data emphasized that all the patients 52
(100%) received antibiotics, diuretics [Frusemide and/or
Spironolactone] in 45 (86.5%), calcium channel blockers
[Diltiazem] in 35 (67.3%), angiotensin converting enzyme
(ACE) inhibitors [Captopril] in 13 (25%), Phosphodiesterase
inhibitors (PDE5) Sildenafil in 17 (32.7%), bronchodilators
in 38 (73%), steroids in 11 (21.2%) and lastly anticoagulants
[heparin and/or warfarin] in 5 (9.6%). These medications were
given either singly or in combinations.
Results of the questionnaire
Among the 40 physicians enrolled in the survey only 15
(37.5%) acknowledged that they found PH a commonly diag-
nosed disease in their practice and the majority 32 (80%)
recorded that it is usually a complication for COPD while 13
(32.5%) credit it to ILD. Lower limb edema and/or elevated
jugular venous pressure were the commonest two clinical find-
ings that 35 (87.5%) physicians agreed upon when asked when
to suspect the patient developed PH whereas 15 (37.5%)
referred to the development of unexplained dyspnea and only
4 (10%) considered the presence of P-pulmonale and right axis
deviation in ECG. It is significant to mention that each
physician had more than one answer. Moreover 31 (77.5%)
physicians cared to inspect the chest X-ray findings, almostall the physicians 37 (92.5%) concurred on investigating the
patients to confirm the diagnosis of PH once suspected. As
regards the method of investigation; 34 (85%) decided on
ECHO only but 5 (12.5%) recommended both ECG and
ECHO. Idiopathic PH was suspected by the presence of
unexplained dyspnea with normal CXR as stated by 30
(75%) physicians, the rest 10 (25%) were not knowledgeable.
To reach a confirmed diagnosis of PH only 2 (5%) selected
right heart catheterization while 35 (87.5%) chose elevated
RVSP > 25 mmHg and 3 (7.5%) did not know. Regarding
the referral of the PH cases to specialized centers only 11
(27.5%) agreed; 10 (25%) physicians start to care for PH cases
since the year 2005, 4 (10%) started since 2000 and 2 (5%) did
not. Furthermore 14 (35%) of the physicians were managing
>30 patients, 7 (17.5%) were managing 20–30 patients, 11
(27.5%) were managing 1–10 patients and 8 (20%) weren’t
managing any at the time of the questionnaire. Only 6 (15%)
of the involved physicians requested right heart catheterization
with vasodilator testing prior to prescribing a therapy for PH.
As regards the different types of medications prescribed it is
illustrated in Fig. 3. None of the physicians conducted clinical
trials on PH medications also none of them have previously
referred any of the PH cases for heart and lung transplant
and only 1 physician referred 1 case for thrombo-
endarterectomy. Lastly and unfortunately 34 (85%) of the
physicians didn’t attend any educational meeting concerning
PH, the remaining 4 (10%) attended one meeting and 2
(5%) attended two meetings.
Discussion
This study recorded that the mean age of the enrolled patient
was (55.8 ± 13.25) years demonstrating that PH is now more
frequently diagnosed in elderly patients matching with studies
done by Gartman et al. [8] (55 ± 10) years and Fayngersh
et al. [9] (63 ± 10.2) years. In addition it was in agreement
with many registries as the Scottish-SMR [10] (52 ± 12) years,
the Spanish [11] (52 ± 12) years and the US REVEAL [12] (50
± 14) years although their selected population involved only
group 1. However it wasn’t in accord with the NIH registry
[13] (36 ± 15) years nor the new Chinese registry [14] (36
± 13) years. The changing phenotype of PH could be
explained by the fact that the NIH registry of the selected
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meanwhile the dissimilarity from the Chinese registry could be
related to the different healthcare environment independent to
the disease expressions The female predominance (53.8%) in
this study though not much, was also consistent with the pre-
vious registries [10–12]. Data in this study revealed that (50%)
half of the diagnosed female patients were housewives and
lived in the capital city Cairo. This could be attributed to the
better awareness of the urban doctors than the rural ones as
well as the abundance of specialized medical centers and hos-
pitals distributed all over the vast city. Cigarette smoke-
induced pulmonary hypertension is associated with evidence
of oxidative vascular damage by reactive nitrogen species lead-
ing to pulmonary vascular remodeling [15]. This was witnessed
by the presence of 23 (44.2%) cigarette smokers among the
cases with a mean of 3.9 (±1.6) packs/day and a mean cigar-
ette smoking index of 78.5 (±33.3). As regards the co-morbid
diseases hypertension (46.2%) and type II diabetes mellitus
(17.3%) were the commonest conforming with the findings
of Ling et al. [16]. There is no pathognomonic clinical sign
of PH; clinical presentation is related either to right heart fail-
ure or to associated diseases. Persistent dyspnea on exertion is
the most frequent symptom; and it is present in almost all
patients even in the presence of mild hemodynamic abnormal-
ities. Dyspnea usually starts insidiously and is often neglected
by patients which explain the delay of around two years in
establishing the diagnosis of PH [17]. The study showed that
dyspnea was the most prevalent symptom being manifested
by all patients (100%), followed by chest wheeze (40.4%),
cough (28.8%) orthopnea (23.1%), chest pain (3.8%), hemop-
tysis (3.8%), and elevated body temperature (7.7%) showing
concordance with results of Ling et al. [16], Edelman [18]
and Jing et al. [14]. Baseline functional class (FC) is an impor-
tant correlate and predictor of survival. The modified New
York Heart Association (NYHA) FC is a simple, reproducible
and clinically important assessment tool and prognostic mea-
sure in PH patients both at the time of diagnosis and in follow
up [19]. The cases in this study were classified according to the
NYHA FC into two groups. The majority fitted in FC III
40/52 (76.9%) and only 12/52 (23.1%) into FC IV correspond-
ing to the findings of Hurdman et al. [20] who found that 47%
of patients were FC III at diagnosis superior to 20% who were
in FC IV. It was also matching the results of Soliman et al. [21]
as all studied groups resided in FC III (36%) and FC IV
(55%). The study registered that lower limb edema (90.4%)
was the most prevalent sign followed by congested neck vein
(77%) then wheeze (76.9%). Cardiac examination revealed
that TR murmur was the commonest (46.2%) followed by
audible S3 (23.1%), accentuated S2 (21.2%) and Splitting of
S2 This did not agree with Colman et al. [22] and Jing et al.
[14] who both found that the sign most associated with PH
was a loud pulmonic component of the second heart sound
(P2). The ABG analysis for the patients revealed that all the
patients suffered from slight respiratory acidosis with a mean
pH of 7.3 (±0.03) explained by the elevated mean PaCO2 of
49.9 (±8.6) mmHg and hypoxemia explained by a mean
PaO2 of 73.6 (±12.7) mmHg, and a mean SO2 of 83.9
(±5)%. The mean HCO3 was 28.5 (±6.9) mmol/L and the
mean ABE was 5.19 (± 6.6) mEq/L. The hypoxemia could
be regarded as either a causal factor for PH as sustained alve-
olar hypoxia induces pulmonary vascular remodeling or a con-
sequence of the disease itself [23]. The hypoventilation mightbe related to affection of ventilatory reserve by PH or the fact
that the majority of the cases where COPD similarly to the
results of Soliman et al. [21] and Hurdman et al. [20].
Among the 52 ECG reports collected two predominant
findings were noticed equally in the form right axis deviation
and P pulmonale in 33 (63%) and this agreed with Jing et al.
[14] and Bossone et al. [6].
The right ventricle plays an important role in the morbidity
and mortality of patients presenting with signs and symptoms
of cardiopulmonary disease. However, the systematic assessment
of right heart function is not uniformly carried out. This is due
partly to the enormous attention given to the evaluationof the left
heart, lack of familiarity with ultrasound techniques that can be
used in imaging the right heart, and a paucity of ultrasound stud-
ies providing normal reference values of right heart size and func-
tion [24]. Unfortunately this applies to this study since data were
collected retrospectively;ECHOassessment of the right heartwas
defective and represents one of the limitations of this study. The
diagnostic methodology used in the studies was not always the
same; some used echocardiography as a sole diagnostic tool,
while othersused right heart catheterization (RHC)as it is consid-
ered the ‘‘gold standard” for the diagnosis of PAH [25]. In this
study retrospective ECHO assessment records revealed an ele-
vated right ventricular systolic pressure (RVSP)withanestimated
mean of 61.4 (±12.4) mmHg, tricuspid regurge was the most
common valve affection in 38 (73%) of the cases while 18
(34.6%) had left ventricular diastolic dysfunction and left ventric-
ular hypertrophy. It is important to note that some patients had
more than one abnormality detected.
PH due to lung diseases and/or hypoxia (group 3 according
to the updated classification of PH) constituted the majority of
cases 43/52 (82.6%) mostly chronic obstructive pulmonary dis-
ease (COPD) 29/52 (55.7%). PH due to left sided heart failure
was the second common cause 5/52 (9.6%) followed equally by
patients with chronic thromboembolism (CTEPH) (group 4)
2/52 (3.8%) and patients with idiopathic pulmonary hyperten-
sion (group 1) 2/52 (3.8%). The results didn’t conform with the
findings of many studies as Mueller-Mottet et al. [26], Idrees
et al. [27] 2014 and Jansa et al. [28] 2014. The discrepancies
in the results could be attributed to many factors, firstly the
variable populations, enrollment pattern and cohort size
among the different studies. Secondly the profile of PH and
patients characteristics varies around the world. Thirdly group
3 (PH due to chronic lung disease and/or hypoxia) and group 2
(PH due to left heart diseases) represent an increasing part of
the clinical practice especially among cases admitted to chest
hospitals where this study took place.
Analysis of medications received by the patients emphasized
that all patients 52 (100%) received antibiotics, followed by
diuretics [Frusemide and/or Spironolactone] in 45 (86.5%), cal-
cium channel blockers [Diltiazem] in 35 (67.3%), angiotensin
converting enzyme (ACE) inhibitors [Captopril] in 13 (25%),
Phosphodiesterase inhibitors (PDE5) Sildenafil in 17 (32.7%),
bronchodilators in 38 (73%), steroids in 11 (21.2%) and lastly
anticoagulants [heparin and/or warfarin] in 5 (9.6%). These
medications were given either singly or in combinations.
Data from all over the world indicate that the majority of
patients are still diagnosed in a late stage of the disease, and
this is not expected to change in the near future Hoeper
et al. [29]. Consequently another aim of this thesis was to
conduct a survey to evaluate the awareness of pulmonary
hypertension among chest physicians in Abbasia Chest Hospi-
300 M. Farrag et al.tal. This questionnaire was crafted to better understand refer-
rals, diagnosis and treatment patterns of the patient popula-
tion with suspected pulmonary hypertension among health
care providers. This will help to identify the pitfalls in the prac-
tice and the needed tools and/or evidence based programs to
ensure early diagnosis and goal oriented therapy in pulmonary
hypertension patients. The questionnaire included 18 questions
about the prevalence (Q1, 12 and 2), caring about pulmonary
hypertension as a disease (Q11), clinical picture (Q3), investi-
gations (Q8, 4–9 and 13) and treatment of pulmonary hyper-
tension (Q10, 14–18). The outcome of the questionnaire
reflected defective awareness as regards the diagnosis and man-
agement of the disease and lack of continuous medical educa-
tion in this field reflected by the fact that 85% of the physicians
didn’t attend educational meetings regarding pulmonary
hypertension in the last 2 years.
The limitations of this study could be attributed mainly to
two factors:
(1) The unavailability of the RHC at the facility where the
study was performed.
(2) The systematic assessment of the right heart side using
ECHO was not uniformly carried out therefore retro-
spective collection the data was perplexing.
Conclusion
In conclusion the study provides information on the clinical
and epidemiological features of PH in Egypt as a primary pilot
registry. It was demonstrated that PH due to lung diseases and/
or hypoxia (group 3 according to the updated classification of
PH) constituted the majority of cases 43/52 (82.6%) mostly
chronic obstructive pulmonary disease (COPD) 28/52
(53.8%). Echocardiography provides several variables which
correlate with right heart hemodynamics including PAP, and
should be used as a non invasive screening tool but not as a sub-
stitute to the RHC. Female gender, smoking, COPD and
hypertension were the most prevalent risk factors for PH
among the studied patients. Combination of nonspecific ther-
apy was the mainstay in treating pulmonary hypertension. Fur-
thermore it highlights the fact that awareness about the disease
is still lacking among physicians and/or health care providers
and late detection continues to be a threat for optimum man-
agement of PH. Lastly it unveiled the urgent need for a large
scale registry not only national but also regional using uniform
diagnostic criteria based on the latest published guidelines. This
objective will permit a broader understanding of the disease
and the development of new hypothesis in its management.
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